AMGN
AMGEN INC
$339.30
+0.56%
$183.1B
No data for this timeframe.
Vol
Market Cap$183.1B
Cap SizeLarge Cap
Analyst ConsensusHold (48%)
Inst. Holders9 funds
Inst. Value$34.7B
Inst. Activity2 buys / 1 sells
SEC Reports6
Congressional6 trades
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000318154·Prev Close $337.42
Recent Activity
Aug 3, 2026
earnings_calendar
AMGN Q2 2026 Earnings After Market Close — 2026-08-03
EPS est: $5.88 | Rev est: $9.6B
May 21, 2026
SEC
Canaccord Genuity initiates AMGN at Hold — PT $366 (+10.4%)
ANALYST-UPGRADE — Impact 1/10
May 19, 2026
Insider
Austin Wanda M sold 665 shares
Director @ $0.00 ($0.00)
May 19, 2026
Insider
Druker Brian sold 665 shares
Director @ $0.00 ($0.00)
May 19, 2026
Insider
Drake Michael V sold 665 shares
Director @ $0.00 ($0.00)
May 1, 2026
SEC
William Blair upgrades AMGN to Outperform from Market Perform — no price target set; consensus implies +1.9% upside to $352.73
ANALYST-UPGRADE — Impact 1/10
Apr 21, 2026
SEC
Canaccord Genuity initiates AMGN at Hold with $366 PT — 4.5% upside, ahead of earnings
ANALYST-UPGRADE — Impact 1/10
Inst.
NORGES BANK — NEW
6,611,965 shares ($2.2B)
Price Targets
$352.23
+3.8% upside
Hold
Current $339.30
Low $200.00
Median $352.50
High $427.00
30 analysts
$200.00
$427.00
Analyst Ratings
6Strong Buy
15Buy
20Hold
2Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| May 4, 2026 | Guggenheim | MAINTAIN | Neutral → Neutral |
| May 1, 2026 | Truist Securities | MAINTAIN | Hold → Hold |
| Apr 21, 2026 | Canaccord Genuity | INITIATE | Hold |
| Apr 13, 2026 | UBS | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $5.59 ▼ -3.2% | $4.99 — $6.28 | -7% YoY | 26 |
| Next Q | $5.76 ▼ -0.9% | $5.06 — $6.15 | 2% YoY | 26 |
| Current FY | $22.41 | $21.70 — $23.01 | 3% YoY | 33 |
| Next FY | $23.48 ▲ +0.7% | $21.46 — $24.88 | 5% YoY | 34 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $17.9B | — |
| MORGAN STANLEY | $5.2B | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.9B | ADD |
| WELLS FARGO & COMPANY/MN | $2.3B | — |
| NORGES BANK | $2.2B | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | Austin Wanda | A | $0.00 |
| May 19, 2026 | Druker Brian | A | $0.00 |
| May 19, 2026 | Drake Michael | A | $0.00 |
| May 19, 2026 | Garland Greg | A | $0.00 |
| May 19, 2026 | ECKERT ROBERT | A | $0.00 |
Congressional Trades
3 members: 1 buys, 5 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Maria Elvira | R | SELL | $15,001 - $50,000 |
| Mark Warner | D | SELL | $1,001 - $15,000 |
| Mark Warner | D | SELL | $1,001 - $15,000 |
9 institutional holders with $34.7B total value (105,986,093 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 54,838,826 | $17.9B | 51.7% | — |
| 2 | MORGAN STANLEY | 15,744,528 | $5.2B | 14.9% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 11,811,045 | $3.9B | 11.1% | ADD +25.4% |
| 4 | WELLS FARGO & COMPANY/MN | 7,112,793 | $2.3B | 6.7% | — |
| 5 | NORGES BANK | 6,611,965 | $2.2B | 6.2% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 5,537,361 | $1.8B | 5.2% | — |
| 7 | FMR LLC | 3,592,220 | $1.2B | 3.4% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 723,988 | $237.0M | 0.7% | DOUBLED +835.1% |
| 9 | DODGE & COX | 13,367 | $4.4M | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 6,611,965 | — | $2.2B | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 77,425 | 723,988 | +835.1% | $237.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 167,245 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 277,300 | 167,245 | -39.7% | $47.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 3,243 | 77,425 | +2287.4% | $21.8M | 2025-Q3 |
| NORGES BANK | EXIT | 5,958,689 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 5,958,689 | — | $1.7B | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 114,400 | 277,300 | +142.4% | $77.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 359,516 | 3,243 | -99.1% | $905.5K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 3,414,803 | 2,345,905 | -31.3% | $730.9M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 902,286 | 359,516 | -60.2% | $112.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 69,045 | 114,400 | +65.7% | $35.6M | 2025-Q1 |
| NORGES BANK | EXIT | 5,916,171 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 10,532,629 | 13,205,604 | +25.4% | $3.4B | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 2,077,304 | 3,414,803 | +64.4% | $890.0M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 69,045 | — | $18.0M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 10,532,629 | — | $3.4B | 2024-Q3 |
22 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | Austin Wanda M | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | Druker Brian | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | Drake Michael V | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | Garland Greg C. | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | ECKERT ROBERT | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | HOLLEY CHARLES M | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | ISHRAK OMAR | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | Jacks Tyler | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | Klotman Mary E. | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | Kullman Ellen Jamison | Director | A | 665 | $0.00 | $0.00 |
| May 19, 2026 | MILES AMY E | Director | A | 665 | $0.00 | $0.00 |
| May 7, 2026 | REESE DAVID M | EVP & Chief Technology Officer | F | 556 | $331.11 | $184.1K |
| May 7, 2026 | Bradner James E. | EVP, Research and Development | F | 446 | $331.11 | $147.7K |
| May 7, 2026 | Bradway Robert A | Chairman, CEO and President | F | 2,079 | $331.11 | $688.4K |
| May 7, 2026 | Gordon Murdo | EVP, Global Commercial Ops | F | 615 | $331.11 | $203.6K |
| May 7, 2026 | Graham Jonathan P | EVP & Gen. Counsel & Sec. | F | 499 | $331.11 | $165.2K |
| May 7, 2026 | Griffith Peter H. | EVP & CFO | F | 556 | $331.11 | $184.1K |
| May 7, 2026 | Grygiel Nancy A. | SVP & CCO | F | 88 | $331.11 | $29.1K |
| May 7, 2026 | Khosla Rachna | SVP, Business Development | F | 93 | $331.11 | $30.8K |
| May 7, 2026 | Miller Derek | SVP, Human Resources | F | 151 | $331.11 | $50.0K |
| May 7, 2026 | Santos Esteban | EVP, Operations | F | 522 | $331.11 | $172.8K |
| May 7, 2026 | Busch Matthew C. | VP, Finance & CAO | F | 41 | $331.11 | $13.6K |
| May 6, 2026 | Bradner James E. | EVP, Research and Development | F | 407 | $329.59 | $134.1K |
| May 6, 2026 | Bradway Robert A | Chairman, CEO and President | F | 1,702 | $329.59 | $561.0K |
| May 6, 2026 | Busch Matthew C. | VP, Finance & CAO | F | 50 | $329.59 | $16.5K |
| May 6, 2026 | Gordon Murdo | EVP, Global Commercial Ops | F | 502 | $329.59 | $165.5K |
| May 6, 2026 | Graham Jonathan P | EVP & Gen. Counsel & Sec. | F | 408 | $329.59 | $134.5K |
| May 6, 2026 | Griffith Peter H. | EVP & CFO | F | 502 | $329.59 | $165.5K |
| May 6, 2026 | Grygiel Nancy A. | SVP & CCO | F | 76 | $329.59 | $25.0K |
| May 6, 2026 | Khosla Rachna | SVP, Business Development | F | 79 | $329.59 | $26.0K |
| May 6, 2026 | Miller Derek | SVP, Human Resources | F | 123 | $329.59 | $40.5K |
| May 6, 2026 | REESE DAVID M | EVP & Chief Technology Officer | F | 454 | $329.59 | $149.6K |
| May 6, 2026 | Santos Esteban | EVP, Operations | F | 427 | $329.59 | $140.7K |
| May 5, 2026 | Bradner James E. | EVP, Research and Development | A | 21,773 | $329.59 | $7.2M |
| May 5, 2026 | Bradner James E. | EVP, Research and Development | A | 3,337 | $0.00 | $0.00 |
| May 5, 2026 | Bradway Robert A | Chairman, CEO and President | A | 79,176 | $329.59 | $26.1M |
| May 5, 2026 | Bradway Robert A | Chairman, CEO and President | A | 12,136 | $0.00 | $0.00 |
| May 5, 2026 | Busch Matthew C. | VP, Finance & CAO | A | 2,969 | $329.59 | $978.6K |
| May 5, 2026 | Busch Matthew C. | VP, Finance & CAO | A | 455 | $0.00 | $0.00 |
| May 5, 2026 | Gordon Murdo | EVP, Global Commercial Ops | A | 23,752 | $329.59 | $7.8M |
| May 5, 2026 | Gordon Murdo | EVP, Global Commercial Ops | A | 3,640 | $0.00 | $0.00 |
| May 5, 2026 | Graham Jonathan P | EVP & Gen. Counsel & Sec. | A | 17,022 | $329.59 | $5.6M |
| May 5, 2026 | Graham Jonathan P | EVP & Gen. Counsel & Sec. | A | 2,609 | $0.00 | $0.00 |
| May 5, 2026 | Griffith Peter H. | EVP & CFO | A | 23,752 | $329.59 | $7.8M |
| May 5, 2026 | Griffith Peter H. | EVP & CFO | A | 3,640 | $0.00 | $0.00 |
| May 5, 2026 | Grygiel Nancy A. | SVP & CCO | A | 485 | $0.00 | $0.00 |
| May 5, 2026 | Khosla Rachna | SVP, Business Development | A | 3,266 | $329.59 | $1.1M |
| May 5, 2026 | Khosla Rachna | SVP, Business Development | A | 500 | $0.00 | $0.00 |
| May 5, 2026 | Miller Derek | SVP, Human Resources | A | 5,938 | $329.59 | $2.0M |
| May 5, 2026 | Miller Derek | SVP, Human Resources | A | 910 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 5 neutral. Avg impact: 2.0/10.
NEUTRAL
ANALYST-UPGRADE
1/10
Canaccord Genuity initiates AMGN at Hold with $366 PT — 4.5% upside, ahead of earnings
Apr 21, 2026
MIXED
ANALYST-UPGRADE
1/10
William Blair upgrades AMGN to Outperform from Market Perform — no price target set; consensus implies +1.9% upside to $352.73
May 1, 2026
NEUTRAL
ANALYST-UPGRADE
1/10
Canaccord Genuity initiates AMGN at Hold — PT $366 (+10.4%)
May 21, 2026
NEUTRAL
8-K
3/10
Amgen CFO Peter Griffith is retiring effective August 31, 2026, with a transition period through Jan
May 19, 2026
NEUTRAL
8-K
3/10
Amgen announced the retirement of David M. Reese, Executive Vice President and Chief Technology Offi
Apr 22, 2026
NEUTRAL
DEFA14A
3/10
Amgen is holding its 2026 annual meeting to vote on director elections, executive compensation, audi
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (48% buy). Based on 44 analysts: 6 strong buy, 15 buy, 20 hold, 2 sell, 1 strong sell.
Analyst Price Targets
$352.23 mean target
+3.8% upside
Hold (2.46)
$200.00 Low
$427.00 High
| Metric | Value |
|---|---|
| Current Price | $339.30 |
| Target Low | $200.00 |
| Target Mean | $352.23 |
| Target Median | $352.50 |
| Target High | $427.00 |
| # Analysts | 30 |
| Recommendation | Hold (2.46) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$5.59 | $4.99 | $6.28 | -7.1% | -3.2% | 3↑ 18↓ | $9.4B | 2.6% | 26 |
| Next Q 2026-09-30 |
$5.76 | $5.06 | $6.15 | 2.1% | -0.9% | 6↑ 15↓ | $9.7B | 1.4% | 26 |
| Current FY 2026-12-31 |
$22.41 | $21.70 | $23.01 | 2.6% | +0.2% | 19↑ 11↓ | $37.8B | 2.8% | 33 |
| Next FY 2027-12-31 |
$23.48 | $21.46 | $24.88 | 4.8% | +0.7% | 15↑ 12↓ | $38.8B | 2.5% | 34 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $5.590 | |
| 7d ago | $5.624 | -0.034 |
| 30d ago | $5.773 | -0.183 |
| 60d ago | $5.830 | -0.240 |
| 90d ago | $5.790 | -0.200 |
16 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| May 4, 2026 | Guggenheim | MAINTAIN | Neutral | Neutral |
| May 1, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Apr 21, 2026 | Canaccord Genuity | INITIATE | — | Hold |
| Apr 13, 2026 | UBS | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 9, 2026 | Guggenheim | MAINTAIN | Neutral | Neutral |
| Apr 8, 2026 | Cantor Fitzgerald | REITERATE | Neutral | Neutral |
| Mar 10, 2026 | Jefferies | INITIATE | — | Hold |
| Feb 20, 2026 | Barclays | INITIATE | — | Equal-Weight |
| Feb 19, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 18, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 12, 2026 | Freedom Broker | DOWNGRADE | Buy | Hold |
| Feb 6, 2026 | Argus Research | MAINTAIN | Buy | Buy |
| Feb 6, 2026 | Guggenheim | MAINTAIN | Neutral | Neutral |
| Feb 4, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 4, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 4, 2026 | Cantor Fitzgerald | MAINTAIN | Neutral | Neutral |
| Feb 4, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Jan 26, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Bernstein | DOWNGRADE | Outperform | Market Perform |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Dec 12, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Dec 10, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Dec 3, 2025 | BMO Capital | MAINTAIN | Outperform | Outperform |
| Nov 27, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 6 | 15 | 20 | 2 | 1 | 48% | |
| Apr 1, 2026 | 6 | 15 | 19 | 2 | 1 | 49% | |
| Mar 1, 2026 | 6 | 15 | 18 | 2 | 1 | 50% | |
| Feb 1, 2026 | 6 | 16 | 16 | 2 | 1 | 54% | |
| Jan 1, 2026 | 7 | 15 | 16 | 2 | 1 | 54% | |
| Dec 1, 2025 | 7 | 15 | 16 | 2 | 1 | 54% | |
| Nov 1, 2025 | 7 | 14 | 16 | 2 | 1 | 53% |
Strong BuyBuyHoldSellStrong Sell
3 members of Congress traded this stock: 1 buys, 5 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | Maria Elvira Salazar | R | HOUSE | SELL | $15,001 - $50,000 | Amgen Inc | May 11, 2026 (25d) |
| Apr 7, 2026 | Mark Warner | D | SENATE | SELL | $1,001 - $15,000 | Amgen Inc | May 1, 2026 (25d) |
| Apr 7, 2026 | Mark Warner | D | SENATE | SELL | $1,001 - $15,000 | Amgen Inc | May 1, 2026 (25d) |
| Apr 6, 2026 | Mark Warner | D | SENATE | SELL | $1,001 - $15,000 | Amgen Inc | May 1, 2026 (26d) |
| Mar 24, 2026 | Maria Elvira Salazar | R | HOUSE | BUY | $15,001 - $50,000 | Amgen Inc | Apr 22, 2026 (30d) |
| Feb 26, 2026 | David Taylor | R | HOUSE | SELL | $1,001 - $15,000 | Amgen Inc | Mar 9, 2026 (12d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Aug 3, 2026
earnings_calendar
AMGN Q2 2026 Earnings After Market Close — 2026-08-03
EPS est: $5.88 | Rev est: $9.6B
May 23, 2026
Clinical Trial
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Phase Phase 2 — COMPLETED
May 23, 2026
clinical_trial_readout
Results Pending: Anvumetostat (Phase 2) — Completed 87d ago
Trial: A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid
May 21, 2026
Clinical Trial
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 21, 2026
clinical_trial_readout
T-90d Trial Readout: Dazodalibep (Phase 3)
Trial: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Diseas
May 20, 2026
short_volume
Short Volume: AMGN — 62.1% short (0.8M / 1.3M)
Short: 804,538 | Exempt: 204 | TRF Vol: 1,295,763 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
Clinical Trial
Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial
Phase Phase 3 — COMPLETED
May 19, 2026
short_volume
Short Volume: AMGN — 58.1% short (0.5M / 0.8M)
Short: 484,985 | Exempt: 625 | TRF Vol: 835,120 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 18, 2026
Clinical Trial
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Apremilast (Phase 3)
Trial: A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Sponsor: Amgen
Phase: Phase 3 | Status: ACTI
May 15, 2026
short_volume
Short Volume: AMGN — 68.4% short (0.5M / 0.7M)
Short: 510,612 | Exempt: 392 | TRF Vol: 746,760 | Short Ratio: 68.4% | Off-exchange volume (dark pool + OTC)
May 14, 2026
Clinical Trial
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
Phase Phase 2 — TERMINATED
May 12, 2026
short_volume
Short Volume: AMGN — 61.7% short (0.4M / 0.6M)
Short: 386,985 | Exempt: 572 | TRF Vol: 627,075 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Apremilast (Phase 3)
Trial: A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Sponsor: Amgen
Phase: Phase 3 | Status: ACTI
May 11, 2026
short_volume
Short Volume: AMGN — 61.2% short (0.3M / 0.6M)
Short: 338,410 | Exempt: 545 | TRF Vol: 553,001 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
May 8, 2026
clinical_trial_readout
T-90d Trial Readout: Apremilast (Phase 3)
Trial: A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Sponsor: Amgen
Phase: Phase 3 | Status: ACTI
May 8, 2026
short_volume
Short Volume: AMGN — 63.9% short (0.4M / 0.6M)
Short: 366,981 | Exempt: 1,490 | TRF Vol: 574,308 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: AMGN — 61.9% short (0.9M / 1.5M)
Short: 931,878 | Exempt: 247 | TRF Vol: 1,504,901 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
AMGN Q1 2026 Earnings After Market Close — 2026-04-30
Apr 30, 2026
short_volume
Short Volume: AMGN — 62.4% short (0.6M / 1.0M)
Short: 638,561 | Exempt: 920 | TRF Vol: 1,023,220 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
FDA
PAVBLU
Supplemental Approval — Bioequivalence — AFLIBERCEPT-AYYH — INJECTABLE — INTRAVITREAL
Dec 26, 2024
FDA
WEZLANA
Supplemental Approval — Efficacy — USTEKINUMAB-AUUB — INJECTABLE — SUBCUTANEOUS
May 28, 2024
FDA
BKEMV
Original Approval — Type 2 - New Active Ingredient — ECULIZUMAB-AEEB — INJECTABLE — INTRAVENOUS